We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+10.61%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$1.92B
AUM Growth
+$154M
Cap. Flow
+$53M
Cap. Flow %
2.76%
Top 10 Hldgs %
26.22%
Holding
151
New
15
Increased
40
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
JELD icon
JELD-WEN Holding
JELD
+$18.8M
2
LII icon
Lennox International
LII
+$14.6M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.18M
4
TTD icon
Trade Desk
TTD
+$8.01M
5
VRNS icon
Varonis Systems
VRNS
+$7.91M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$21.1M
2
CYBR
CyberArk
CYBR
+$14M
3
ABBV icon
AbbVie
ABBV
+$10.1M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$9.2M
5
XPO icon
XPO
XPO
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 40.8%
2 Technology 16.87%
3 Consumer Discretionary 13.92%
4 Industrials 10.12%
5 Utilities 5.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.77B
$6.86M 0.36%
313,000
– –
ZGNX
77
DELISTED
Zogenix, Inc.
ZGNX
$6.73M 0.35%
+168,000
New +$6.45M
BMRN icon
78
BioMarin Pharmaceuticals
BMRN
$12.5B
$6.69M 0.35%
75,000
– –
BHVN
79
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.53M 0.34%
242,000
+188,760
+355% +$5.2M
IFRX icon
80
InflaRx
IFRX
$298M
$5.76M 0.3%
+275,000
New +$4.96M
PTGX icon
81
Protagonist Therapeutics
PTGX
$9.28B
$5.72M 0.3%
275,000
+150,000
+120% +$2.66M
EXAS
82
DELISTED
Exact Sciences
EXAS
$5.25M 0.27%
100,000
– –
SUPN icon
83
Supernus Pharmaceuticals
SUPN
$2.4B
$5.18M 0.27%
130,000
– –
ATHN
84
DELISTED
Athenahealth, Inc.
ATHN
$4.92M 0.26%
37,000
– –
LKFT
85
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$4.88M 0.25%
52,000
– –
MYOK
86
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$4.63M 0.24%
110,000
+37,000
+51% +$1.43M
PRTA icon
87
Prothena Corp
PRTA
$428M
$4.5M 0.23%
120,000
– –
DBVT
88
DBV Technologies
DBVT
$739M
$4.18M 0.22%
17,000
– –
RARE icon
89
Ultragenyx Pharmaceutical
RARE
$1.29B
$4.05M 0.21%
87,400
– –
RGEN icon
90
Repligen
RGEN
$9.86B
$3.99M 0.21%
110,000
– –
ACRS icon
91
Aclaris Therapeutics
ACRS
$814M
$3.45M 0.18%
140,000
– –
DERM
92
DELISTED
Dermira, Inc.
DERM
$3.45M 0.18%
124,000
– –
FRTX
93
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$3.11M 0.16%
+5,397
New +$3.56M
TCON
94
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$3.02M 0.16%
4,500
– –
TTPH
95
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.92M 0.15%
23,185
– –
IRWD icon
96
Ironwood Pharmaceuticals
IRWD
$671M
$2.88M 0.15%
229,248
– –
NTUS
97
DELISTED
Natus Medical Inc
NTUS
$2.87M 0.15%
75,000
– –
REGN icon
98
Regeneron Pharmaceuticals
REGN
$79.7B
$2.82M 0.15%
7,500
– –
MGNX icon
99
MacroGenics
MGNX
$257M
$2.79M 0.15%
147,000
– –
DLPH
100
DELISTED
Delphi Technologies PLC Ordinary Shares
DLPH
$2.76M 0.14%
+52,666
New +$2.74M
2 3
4
5 6

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Eventide Asset Management held 151 positions worth $1.92B, up 8.7% from $1.76B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management's Q4 2017 filing shows 15 new, 40 increased, 15 reduced and 11 closed positions. Its largest new stake was JELD-WEN Holding: 506,500 shares worth $19.9M. The largest sale was bluebird bio, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 42% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q4 2017 buy was JELD-WEN Holding: 506,500 shares worth $19.9M.
  • Eventide Asset Management added most to AveXis, Inc. Common Stock in Q4 2017, an estimated $8.18M increase.
  • Eventide Asset Management's biggest Q4 2017 reduction was bluebird bio, cutting an estimated $21.1M.
  • Eventide Asset Management fully exited CyberArk in Q4 2017, selling an estimated $14M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $1.92B portfolio in Q4 2017.
  • Eventide Asset Management opened 15 new positions and closed 11 in Q4 2017.
  • Eventide Asset Management's portfolio value rose 8.7% quarter-over-quarter to $1.92B.

Based on Eventide Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.